Literature DB >> 33622411

SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion.

Shu Yang1,2, Hongying Zhang1, Hua Yang3, Jin Zhang1, Jiao Wang4, Ting Luo5, Yangfu Jiang6, Hui Hua7.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the common cancers that are very aggressive. The secreted cytokine transforming growth factor-β (TGF-β) promotes cancer metastasis by multiple mechanisms such as epithelial-mesenchymal transition and immune evasion. The canonical TGF-β signaling is largely mediated by smooth muscle actin/mothers against decapentaplegic (SMAD) proteins. The current study aims to explore the regulation of TGF-β/SMAD signaling by selenophosphate synthetase 1 (SEPHS1).
METHODS: Immunohistochemistry was used to detect the expression of SEPHS1 in HCC and adjacent liver tissues. Western blotting and quantitative reverse-transcription PCR were used to detect the protein and mRNA levels in HCC cell lines. Cell migration and invasion were determined by transwell assay. Bioinformatic analysis was conducted to determine SEPHS1 expression in HCC and its correlation with the survival of HCC patients.
RESULTS: Here we report that SEPHS1 is a positive regulator of SMAD proteins. SEPHS1 expression is up-regulated in HCC compared with adjacent liver tissues. SEPHS1 knockdown leads to decreased expression of SMAD2/3/4 and mesenchymal markers including snail, slug and N-cadherin in HCC cells. Furthermore, SEPHS1 knockdown results in a decrease in HCC cells migration and invasion, and suppresses the stimulation of HCC cells migration and invasion by TGF-β. Overexpression of SEPHS1 in HCC cells promotes cell invasion, which can be abrogated by SMAD3 knockdown. Lastly, higher expression of SEPHS1 is correlated with poor prognosis in HCC patients, as manifested by decreased overall survival and disease-free survival.
CONCLUSIONS: SEPHS1 is a positive regulator of TGF-β/SMAD signaling that is up-regulated in HCC. Increased SEPHS1 expression may indicate poor prognosis for patients with HCC.

Entities:  

Keywords:  Cancer; SEPHS1; SMAD; TGF-β

Year:  2021        PMID: 33622411      PMCID: PMC7903722          DOI: 10.1186/s40164-021-00212-7

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN: 2162-3619


  35 in total

1.  Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

Authors:  Kate Revill; Tim Wang; Anja Lachenmayer; Kensuke Kojima; Andrew Harrington; Jinyu Li; Yujin Hoshida; Josep M Llovet; Scott Powers
Journal:  Gastroenterology       Date:  2013-09-05       Impact factor: 22.682

Review 2.  TGF-β in epithelial to mesenchymal transition and metastasis of liver carcinoma.

Authors:  Patrick Reichl; Christine Haider; Markus Grubinger; Wolfgang Mikulits
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.

Authors:  Koichi Matsuzaki; Miki Murata; Katsunori Yoshida; Go Sekimoto; Yoshiko Uemura; Noriko Sakaida; Masaki Kaibori; Yasuo Kamiyama; Mikio Nishizawa; Junichi Fujisawa; Kazuichi Okazaki; Toshihito Seki
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

5.  Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes.

Authors:  Kumardeep Chaudhary; Olivier B Poirion; Liangqun Lu; Sijia Huang; Travers Ching; Lana X Garmire
Journal:  Clin Cancer Res       Date:  2018-09-21       Impact factor: 12.531

6.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

Review 7.  Targeting mTOR for cancer therapy.

Authors:  Hui Hua; Qingbin Kong; Hongying Zhang; Jiao Wang; Ting Luo; Yangfu Jiang
Journal:  J Hematol Oncol       Date:  2019-07-05       Impact factor: 17.388

8.  Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis.

Authors:  Yinying Dong; Qiongdan Zheng; Zhiming Wang; Xiahui Lin; Yang You; Sifan Wu; Yaohui Wang; Chao Hu; Xiaoying Xie; Jie Chen; Dongmei Gao; Yan Zhao; Weizhong Wu; Yinkun Liu; Zhenggang Ren; Rongxin Chen; Jiefeng Cui
Journal:  J Hematol Oncol       Date:  2019-11-08       Impact factor: 17.388

Review 9.  Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

Authors:  Diwakar Suresh; Akshatha N Srinivas; Divya P Kumar
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

View more
  3 in total

1.  The role of the Smad2/3/4 signaling pathway in osteogenic differentiation regulation by ClC-3 chloride channels in MC3T3-E1 cells.

Authors:  Xiaolin Lu; Weixu Li; Huan Wang; Meng Cao; Zuolin Jin
Journal:  J Orthop Surg Res       Date:  2022-07-06       Impact factor: 2.677

2.  Gamma synuclein promotes cancer metastasis through the MKK3/6-p38MAPK cascade.

Authors:  Jieya Liu; Ting Shao; Jin Zhang; Qianyi Liu; Hui Hua; Hongying Zhang; Jiao Wang; Ting Luo; Yuenian Eric Shi; Yangfu Jiang
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

Review 3.  Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy.

Authors:  Yangfu Jiang; Hongying Zhang; Jiao Wang; Yongliang Liu; Ting Luo; Hui Hua
Journal:  J Hematol Oncol       Date:  2022-03-24       Impact factor: 17.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.